Literature DB >> 10955348

Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey.

S Plamondon1, P B Dent.   

Abstract

OBJECTIVE: To review the clinical features of juvenile amyopathic dermatomyositis (ADM) to define an appropriate approach to its diagnosis and management.
METHODS: Based on a review of published adult and pediatric cases, a prevalidated, peer reviewed, 3 page questionnaire was sent to all members of the Pediatric Section of the American College of Rheumatology and American Society for Pediatric Dermatology.
RESULTS: Thirty-nine questionnaires were submitted for analysis. Twelve cases were excluded due to abnormal test results. Only one case met all criteria. Although 26 cases were incompletely investigated or had inadequate followup, they were not excluded, as all completed tests were normal. Two patients with incomplete data developed calcinosis. Of 27 patients not positively excluded, 10 were treated systemically, with 5 achieving remission, while 11/17 untreated recovered spontaneously. At a mean followup of 32.8 months from disease onset none of the 27 patients has developed clinical myopathy.
CONCLUSION: The classic skin changes of juvenile DM can occur in the absence of clinical muscle involvement. Physicians are not routinely performing electromyography, muscle biopsy, or magnetic resonance imaging in the assessment of these patients. A significant proportion of patients with ADM will remit without systemic therapy. Optimum treatment needs to be determined through controlled trials.

Entities:  

Mesh:

Year:  2000        PMID: 10955348

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

2.  Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids.

Authors:  Deborah M Levy; C April Bingham; Philip J Kahn; Andrew H Eichenfield; Lisa F Imundo
Journal:  J Pediatr       Date:  2009-10-28       Impact factor: 4.406

Review 3.  Amyopathic dermatomyositis.

Authors:  N J Olsen; J H Park; L E King
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 4.  MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2017-04

Review 5.  The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.

Authors:  L G Rider; K Nistala
Journal:  J Intern Med       Date:  2016-03-30       Impact factor: 8.989

6.  Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis.

Authors:  Gulnara Mamyrova; Takayuki Kishi; Ira N Targoff; Alison Ehrlich; Rodolfo V Curiel; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2018-11-01       Impact factor: 7.580

Review 7.  Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.

Authors:  Hobart W Walling; Pedram Gerami; Richard D Sontheimer
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

Review 8.  Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.

Authors:  Judith Wienke; Claire T Deakin; Lucy R Wedderburn; Femke van Wijk; Annet van Royen-Kerkhof
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.